Brivaracetam for the treatment of epilepsy

J 2016

Brivaracetam for the treatment of epilepsy

KLEIN, Pavel, Ivana TYRLÍKOVÁ, Milan BRÁZDIL and Ivan REKTOR

Basic information

Original name

Brivaracetam for the treatment of epilepsy

Authors

KLEIN, Pavel (840 United States of America), Ivana TYRLÍKOVÁ (203 Czech Republic), Milan BRÁZDIL (203 Czech Republic) and Ivan REKTOR (203 Czech Republic, guarantor, belonging to the institution)

Edition

EXPERT OPINION ON PHARMACOTHERAPY, Abingdon, TAYLOR & FRANCIS LTD, 2016, 1465-6566

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.894

RIV identification code

RIV/00216224:14740/16:00090504

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1517/14656566.2016.1135129

UT WoS

000370165600001

Keywords in English

Synaptic vesicle protein 2A ligand; Brivaracetam; anticonvulsant agent; partial-onset seizures; refractory epilepsy

Abstract

V originále

Introduction: Approximately one third of patients with epilepsy fail to respond to existing medications. Levetiracetam is an effective antiepileptic drug (AED) postulated to act by binding to synaptic vesicle protein 2A. Brivaracetam is a novel high affinity SV2A ligand with approximately 20-fold higher affinity for SV2A protein than levetiracetam. It is at an advanced stage of clinical development for treatment of epilepsy.Areas covered: This article reviews animal data, pharmacokinetics, and phase 1-3 data of Brivaracetam treatment of epilepsy. Brivaracetam has broad-spectrum anticonvulsant activity in animal models.Expert Opinion: Phase 1 studies indicated that single oral doses of 5-800 mg and repeated oral doses of up to 600 mg were well tolerated and showed favorable pharmacokinetic profile. Phase 2 studies indicated good safety and tolerability of brivaracetam in the dose range of 5-150 mg/day and provided proof of concept for efficacy in treating refractory partial onset seizures. Efficacy and safety have been evaluated in 4 phase 3 studies with dose range of 5-200 mg which have demonstrated efficacy in the range of 100-200 mg/day dose and, in most studies, also with 50 mg/day dose, and good safety and tolerability profile across 5-200 mg doses in adjunctive treatment of refractory partial onset seizures.

Files attached

EL_1350892_Brivaracetam_for_the_treatment_of_epilepsy.pdf

Request the author's version of the file

Citovat

KLEIN, Pavel, Ivana TYRLÍKOVÁ, Milan BRÁZDIL and Ivan REKTOR. Brivaracetam for the treatment of epilepsy. EXPERT OPINION ON PHARMACOTHERAPY. Abingdon: TAYLOR & FRANCIS LTD, 2016, vol. 17, No 2, p. 283-295. ISSN 1465-6566. Available from: https://dx.doi.org/10.1517/14656566.2016.1135129.

@article{1350892,
   author = {Klein, Pavel and Tyrlíková, Ivana and Brázdil, Milan and Rektor, Ivan},
   article_location = {Abingdon},
   article_number = {2},
   doi = {http://dx.doi.org/10.1517/14656566.2016.1135129},
   keywords = {Synaptic vesicle protein 2A ligand; Brivaracetam; anticonvulsant agent; partial-onset seizures; refractory epilepsy},
   language = {eng},
   issn = {1465-6566},
   journal = {EXPERT OPINION ON PHARMACOTHERAPY},
   title = {Brivaracetam for the treatment of epilepsy},
   url = {http://www.tandfonline.com/doi/full/10.1517/14656566.2016.1135129},
   volume = {17},
   year = {2016}
}

TY  - JOUR
ID  - 1350892
AU  - Klein, Pavel - Tyrlíková, Ivana - Brázdil, Milan - Rektor, Ivan
PY  - 2016
TI  - Brivaracetam for the treatment of epilepsy
JF  - EXPERT OPINION ON PHARMACOTHERAPY
VL  - 17
IS  - 2
SP  - 283-295
EP  - 283-295
PB  - TAYLOR & FRANCIS LTD
SN  - 14656566
KW  - Synaptic vesicle protein 2A ligand
KW  - Brivaracetam
KW  - anticonvulsant agent
KW  - partial-onset seizures
KW  - refractory epilepsy
UR  - http://www.tandfonline.com/doi/full/10.1517/14656566.2016.1135129
L2  - http://www.tandfonline.com/doi/full/10.1517/14656566.2016.1135129
N2  - Introduction: Approximately one third of patients with epilepsy fail to respond to existing medications. Levetiracetam is an effective antiepileptic drug (AED) postulated to act by binding to synaptic vesicle protein 2A. Brivaracetam is a novel high affinity SV2A ligand with approximately 20-fold higher affinity for SV2A protein than levetiracetam. It is at an advanced stage of clinical development for treatment of epilepsy.Areas covered: This article reviews animal data, pharmacokinetics, and phase 1-3 data of Brivaracetam treatment of epilepsy. Brivaracetam has broad-spectrum anticonvulsant activity in animal models.Expert Opinion: Phase 1 studies indicated that single oral doses of 5-800 mg and repeated oral doses of up to 600 mg were well tolerated and showed favorable pharmacokinetic profile. Phase 2 studies indicated good safety and tolerability of brivaracetam in the dose range of 5-150 mg/day and provided proof of concept for efficacy in treating refractory partial onset seizures. Efficacy and safety have been evaluated in 4 phase 3 studies with dose range of 5-200 mg which have demonstrated efficacy in the range of 100-200 mg/day dose and, in most studies, also with 50 mg/day dose, and good safety and tolerability profile across 5-200 mg doses in adjunctive treatment of refractory partial onset seizures.
ER  -

KLEIN, Pavel, Ivana TYRLÍKOVÁ, Milan BRÁZDIL and Ivan REKTOR. Brivaracetam for the treatment of epilepsy. \textit{EXPERT OPINION ON PHARMACOTHERAPY}. Abingdon: TAYLOR \&{} FRANCIS LTD, 2016, vol.~17, No~2, p.~283-295. ISSN~1465-6566. Available from: https://dx.doi.org/10.1517/14656566.2016.1135129.

Detailed Information on Publication Record